Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for XTL Biopharmaceuticals Ltd. (XTLB)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
5 months ago | Pulse2
About:
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.
Sector:
HealthcareIndustry:
BiotechnologyAddress:
XTL Biopharmaceuticals Ltd. 5 Badner Street Ramat Gan 5218102 IsraelWebsite:
Home